HANDOK Inc.

KSE 002390.KS

HANDOK Inc. Price to Sales Ratio (P/S) on January 14, 2025: 0.29

HANDOK Inc. Price to Sales Ratio (P/S) is 0.29 on January 14, 2025, a -20.15% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

HANDOK Inc. 52-week high Price to Sales Ratio (P/S) is 0.44 on July 08, 2024, which is 51.56% above the current Price to Sales Ratio (P/S).
HANDOK Inc. 52-week low Price to Sales Ratio (P/S) is 0.27 on December 09, 2024, which is -6.90% below the current Price to Sales Ratio (P/S).
HANDOK Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 0.35.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

KSE: 002390.KS

HANDOK Inc.

CEO	Mr. Young-Jin Kim M.B.A.
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	132 Teheran-ro
Employees	938
Sector	Health Care
Industries Pharmaceuticals

Description

Handok Inc. operates as an integrated pharmaceutical company. The company provides ETC and OTC drugs, medical devices, and in-vitro diagnostics instruments and devices. It focuses on various therapeutic areas, such as oncology, diabetes and metabolic disorders, CNS orphan diseases, eye disorders, and other disease areas. The company also offers healthcare products comprising food supplements under the NatureSet and Culturelle brands; food and beverages; and medical nutrition products. Handok Inc. has a strategic collaboration agreement with AUM Biosciences Pte. Ltd. and CMG Pharmaceutical Co. Ltd. for the development, manufacturing, and commercialization of CHC2014, a pan-TRK inhibitor for cancer treatment. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is based in Seoul, South Korea.

Key trends

Past 5 years